Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Molecular Partners ( (MOLN) ) has provided an update.
On March 12, 2026, Molecular Partners AG filed a Form 6-K noting the publication of its 2025 Annual Report, highlighting a year of scientific and financial milestones. The company advanced its lead Radio-DARPin MP0712 into a U.S. Phase 1/2a trial for small cell lung cancer, nominated a second radiopharmaceutical candidate MP0726, and initiated new clinical work with immune cell engager programs MP0317 and MP0533.
During 2025, Molecular Partners strengthened its radiotherapeutics platform through a development pact with Eckert & Ziegler, creation of a radiotherapy-focused scientific advisory board, and the appointment of Martin Steegmaier as chief scientific officer. The company ended 2025 with CHF 93.1 million in cash and short-term deposits and reported a CHF 51.3 million net operating cash outflow, guiding that its resources should fund operations into 2028 while it targets multiple clinical data readouts and pipeline decisions in 2026.
The most recent analyst rating on (MOLN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Molecular Partners stock, see the MOLN Stock Forecast page.
Spark’s Take on MOLN Stock
According to Spark, TipRanks’ AI Analyst, MOLN is a Neutral.
The score is primarily weighed down by weak financial performance (near-zero TTM revenue, ongoing losses, and significant negative free cash flow) despite low leverage. Technicals are slightly negative in the near term with muted momentum, and valuation provides limited support because the company is loss-making and no dividend yield data is available.
To see Spark’s full report on MOLN stock, click here.
More about Molecular Partners
Molecular Partners AG is a clinical-stage biotech company listed on SIX and Nasdaq, pioneering DARPin protein therapeutics for unmet medical needs, particularly in oncology. Its portfolio includes targeted radiopharmaceuticals, such as Radio-DARPins, and next-generation immune cell engagers, developed through proprietary platforms and strategic partnerships in Europe and the U.S.
Average Trading Volume: 4,695
Technical Sentiment Signal: Buy
Current Market Cap: $193.9M
For a thorough assessment of MOLN stock, go to TipRanks’ Stock Analysis page.